Get regular updates to your inbox.
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), is recommending approval of GW Pharmaceutical’s oral cannabidiol solution as an add-on to clobazam (Onfi and Sympazan) for treating seizures in children and adults, ages 2 and older, with Dravet syndrome or  Lennox-Gastaut syndrome. The…
Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of just six such people who’ve made it to adulthood. Neena Nizar doesn’t have to imagine. The 41-year-old English professor at Metro Community College in Elkhorn,…
Planning for a Phase 1 clinical trial to explore the safety and tolerability of escalating doses of EPX-100, a potential oral treatment for Dravet syndrome, is underway, Epygenix Therapeutics, the investigative therapy’s developer, announced. After completion of this first study in healthy individuals, the company plans to initiate…
Oklahoma suffers more tornadoes than any other state, has the highest per-capita rate of women in U.S. prisons, ranks second in the number of teen births per 100,000 teenage girls, and has the nation’s third-highest rate of uninsured residents — with 13.9% of all Oklahomans lacking health coverage. As if…
Screening newborns for genetic diseases with treatments that can prevent crippling or deadly progression, especially for rare disorders, has a ways to go in the United States. No state today tests for all 35 disorders recommended under a federal screening panel, and even in those that come close, rare…
Severe epilepsy in children with Dravet and Lennox-Gastaut syndrome can be safely treated with a medicinal cannabis oil that includes, at low dose, the intoxicating compound in marijuana known as THC, preliminary results of a Phase 1 clinical study suggest. “What makes these results really exciting is it opens up as…
Encoded Therapeutics will further develop its lead precision gene therapy platform for Dravet syndrome and other severe genetic disorders after a financing round brought in $104 million from several investors. The company’s goal is to receive approval and market this platform, which aims to overcome key limitations of…
A new international consortium based in Paris, and funded largely by the 28-member European Union, intends to speed the diagnosis of rare diseases, while also accelerating the development of treatments for the 95% of such illnesses that currently don’t have one. The European Joint Programme on Rare Diseases (EJP…
A genetic phenomenon called double somatic mosaicism was found for a first time in a girl with Dravet syndrome, a case study reports. The study, “Double somatic mosaicism in a child with Dravet syndrome,” was published in Neurology Genetics. Dravet syndrome, a severe type of epilepsy usually…
Zogenix has announced it will resubmit a New Drug Application (NDA) for Fintepla (ZX008), its investigational anti-seizure therapy for patients with Dravet syndrome, likely in the third quarter of this year. The U.S. Food and Drug Administration (FDA) refused the first NDA for Fintepla…
Get regular updates to your inbox.